Intra-arterial Hepatic Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.
증례연속
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: liver-dominant metastatic castration-resistant prostate cancer (mCRPC)
I · Intervention 중재 / 시술
up to six cycles of Lu-PSMA-RLT (median 7
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] These preliminary findings suggest that intra-arterial Lu-PSMA-RLT is feasible and safe in liver-dominant mCRPC. Prospective studies with dosimetry are warranted.
[PURPOSE] To evaluate the safety and feasibility of intra-arterial Lu-PSMA-radioligand therapy (RLT) in patients with liver-dominant metastatic castration-resistant prostate cancer (mCRPC).
APA
Fakkert RK, Braat AJAT, et al. (2026). Intra-arterial Hepatic Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.. Cardiovascular and interventional radiology, 49(2), 324-329. https://doi.org/10.1007/s00270-025-04258-6
MLA
Fakkert RK, et al.. "Intra-arterial Hepatic Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.." Cardiovascular and interventional radiology, vol. 49, no. 2, 2026, pp. 324-329.
PMID
41203980 ↗
Abstract 한글 요약
[PURPOSE] To evaluate the safety and feasibility of intra-arterial Lu-PSMA-radioligand therapy (RLT) in patients with liver-dominant metastatic castration-resistant prostate cancer (mCRPC).
[MATERIALS AND METHODS] Patients received up to six cycles of Lu-PSMA-RLT (median 7.4 GBq) at six-week intervals. Intra-arterial administration in the hepatic artery was off-label and indicated for patients with high hepatic tumour burden. Primary endpoints were safety (clinical and biochemical adverse events) and procedural feasibility. Exploratory efficacy endpoints were prostate-specific antigen (PSA) response and imaging (PET) response.
[RESULTS] Four patients received 16 cycles (10 intra-arterial, six intravenous). All intra-arterial procedures were technically successful and without periprocedural complications. Toxicity was acceptable and comparable to intravenous treatment, comprising mainly grade 1-2 clinical events with occasional grade 3 biochemical abnormalities, and no grade 4-5 clinical toxicities were observed. PSA decreases occurred in two patients (decrease 24-99%), while two patients had increases. Imaging response was more profound for liver metastasis.
[CONCLUSION] These preliminary findings suggest that intra-arterial Lu-PSMA-RLT is feasible and safe in liver-dominant mCRPC. Prospective studies with dosimetry are warranted.
[MATERIALS AND METHODS] Patients received up to six cycles of Lu-PSMA-RLT (median 7.4 GBq) at six-week intervals. Intra-arterial administration in the hepatic artery was off-label and indicated for patients with high hepatic tumour burden. Primary endpoints were safety (clinical and biochemical adverse events) and procedural feasibility. Exploratory efficacy endpoints were prostate-specific antigen (PSA) response and imaging (PET) response.
[RESULTS] Four patients received 16 cycles (10 intra-arterial, six intravenous). All intra-arterial procedures were technically successful and without periprocedural complications. Toxicity was acceptable and comparable to intravenous treatment, comprising mainly grade 1-2 clinical events with occasional grade 3 biochemical abnormalities, and no grade 4-5 clinical toxicities were observed. PSA decreases occurred in two patients (decrease 24-99%), while two patients had increases. Imaging response was more profound for liver metastasis.
[CONCLUSION] These preliminary findings suggest that intra-arterial Lu-PSMA-RLT is feasible and safe in liver-dominant mCRPC. Prospective studies with dosimetry are warranted.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- Prostatic Neoplasms
- Castration-Resistant
- Aged
- Liver Neoplasms
- Lutetium
- Radiopharmaceuticals
- Hepatic Artery
- Feasibility Studies
- Middle Aged
- Prostate-Specific Antigen
- Infusions
- Intra-Arterial
- Treatment Outcome
- Radioisotopes
- 80 and over
- 177Lu-PSMA-radioligand therapy (RLT)
- Feasibility
- Intra-arterial hepatic administration
- Liver-dominant metastases
- Metastatic castration-resistant prostate cancer (mCRPC)
- PET/CT imaging
- Safety
… 외 1개
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.